Search tips
Search criteria 


Logo of canjgastrohepCanadian Journal of Gastroenterology and Hepatology
Can J Gastroenterol Hepatol. 2017; 2017: 8467192.
Published online 2017 February 21. doi:  10.1155/2017/8467192
PMCID: PMC5339575

Metabonomics Research Progress on Liver Diseases


Metabolomics as the new omics technique develops after genomics, transcriptomics, and proteomics and has rapid development at present. Liver diseases are worldwide public health problems. In China, chronic hepatitis B and its secondary diseases are the common liver diseases. They can be diagnosed by the combination of history, virology, liver function, and medical imaging. However, some patients seldom have relevant physical examination, so the diagnosis may be delayed. Many other liver diseases, such as drug-induced liver injury (DILI), alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD), and autoimmune liver diseases, still do not have definite diagnostic markers; the diagnosis consists of history, medical imaging, and the relevant score. As a result, the clinical work becomes very complex. So it has broad prospects to explore the specific and sensitive biomarkers of liver diseases with metabolomics. In this paper, there are several summaries which are related to the current research progress and application of metabolomics on biomarkers of liver diseases.

1. Introduction

Metabolomics is a new discipline of the “postgenomics” period, which constitutes the core of biology systems with genomics, transcriptomics, and proteomics together and is one of the world's most active fields of life science research. The definition of metabonomics was firstly proposed by the Imperial College London, UK, Dr. Nicholson in 1999 [1]. It is a technique by examining the dynamic changes of metabolites to study metabolomic networks of biological systems before and after stimulations or disturbances (such as a specific genetic mutation or environmental change). The object of metabolomics study is endogenous small molecule, of which the relative molecular mass is less than 1000.

Metabolomics has the following advantages [2]. (1) Small changes in gene and protein expression will be reflected and amplified by the metabolite. (2) Study of metabonomics will not need full genome sequencing and a large number of expressed sequence tags (EST). (3) Metabolites are far less than the number of genes and proteins. (4) The physiological or pathological condition of the body can be detected through the analysis of metabolites in biological fluids. (5) As the detected metabolites in different organisms are similar, the use of metabolomics technique is more common.

The commonly used analysis techniques of metabonomics include nuclear magnetic resonance (NMR), gas chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass spectrometry (LC-MS).

The NMR is one of the earliest and most common used techniques [3]. The spectroscopic technique is based on a spin nuclear property that absorbs radiation at the external magnetic field to generate nuclear energy transitions. The advantages of NMR include the demand for small samples, no sample pretreatment, and nondestructive and noninvasive detection. Furthermore, it can obtain the NMR spectrum of a specific living body portion noninvasively and quickly. NMR is the only existing metabolomics analysis technique which can be used in vivo and in situ studies [4].

Currently the most widely used and most effective metabolomics technologies are GC-MS [5] and LC-MS [6]. The former is appropriate to analyze small molecules, thermally stable, volatile, and easily gasified compounds and the latter can analyze the compounds more polar, higher relative molecular mass and lower thermal stability. In clinical studies, due to the use of blood, urine, and tissue samples, these samples are rich in various polar, nonvolatile, and nonvaporized substances, so compared with GC-MS, the applications of LC-MS are more widely used.

The common pattern recognition methods of metabolomics include unsupervised and supervised ones. The unsupervised methods contain principal component analysis (PCA) [7], nonlinear mapping (NLM) [8], hierarchical cluster analysis (HCA) [9], and so on, while the supervised methods include partial least squares-discriminant analysis (PLS-DA) [10] and artificial neural networks (ANN) [11]. The PCA and PLS-DA are the most commonly used methods of pattern recognition.

2. The Application of Metabonomics in Liver Disease

Liver diseases are the worldwide public health problems. Many of them, such as DILI, ALD, NAFLD, and autoimmune liver diseases, lack specific clinical diagnosis markers and the diagnoses consist of history and relevant score, so they have the high subjectivity, inaccuracy, and limitation. With the development of metabolomics, they have become a hot research field and have the broad prospect to explore the sensitive and specific liver diseases' biomarkers.

2.1. Metabonomic Studies on DILI

In the United States, drug-induced acute liver failure accounted for over 50% of all acute liver failure [12]. In China, DILI accounted for about 10% of patients hospitalized with acute hepatitis [13]. Mild DILI only showed elevated transaminase; the severe one might cause liver failure leading to death [14]. Due to the lack of specific and sensitive diagnostic markers of DILI, it is difficult to make early diagnosis and treatment leading to poor prognosis.

Now there are several clinical and experimental metabolomic studies on DILI trying to find the specific and sensitive markers. The main information about those researches is shown in Table 1.

Table 1
The main information about clinical and experimental metabolomic studies on DILI.

As mentioned in Table 1, these metabolites were involved in carbohydrates, lipids, amino acids, bile acids metabolism, and inflammatory response. Although the results varied, they provided the preliminary understanding on the pathophysiological process of DILI and were beneficial for the further study of DILI markers.

2.2. Metabonomics Studies on ALD

Alcoholic liver disease is divided into alcoholic fatty liver, alcoholic hepatitis, alcoholic liver fibrosis, alcoholic liver cirrhosis, and even alcoholic liver cancer. The diagnosis consists of history of drinking, liver function, medical imaging, and clinical symptoms. In general, alcoholic liver disease has no obvious symptoms and most patients will not go for physical examination. When the disease was found, it might have been in advanced stage. In order to find sensitive and specific biomarkers and make early diagnosis, there were several clinical and experimental metabolomic studies on ALD. The main findings are shown in Table 2.

Table 2
The main results of clinical and experimental metabolomic studies on ALD.

As mentioned in Table 2, there were two LC-MS based urinary metabolomic studies which both showed the correlation between indole-3-lactic acid and ALD. This might mean that indole-3-lactic acid could be used as a potential diagnostic marker of ALD.

2.3. Metabonomics Studies on NAFLD

NAFLD ranges from simple nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) to nonalcoholic cirrhosis. Although NAFL is a benign process and can be reversed through diet and exercise, it has the risk of progressing to NASH and nonalcoholic cirrhosis and causing type 2 diabetes (T2MD) [24]. NAFLD lacks sensitive and specific clinic diagnostic biomarkers. With the development of metabolomics, it provides a powerful tool for NAFLD research.

Now there are several clinical and experimental NAFLD metabolomic researches. However, there are still no uniform metabolites which could be used as the diagnostic markers of NAFLD. The details are shown in Table 3.

Table 3
The findings of metabolomic researches on NAFLD.

2.4. Metabonomics Studies of Hepatitis Virus Related Liver Diseases

According to the World Health Organization, about 2 billion people worldwide have been infected with HBV, of which 240 million people are chronically infected with HBV and each year about 650 thousand people died of liver failure, cirrhosis, and hepatocellular carcinoma caused by HBV.

2.4.1. Metabonomics Studies on Chronic Hepatitis B

Natural history of chronic hepatitis B infection is generally divided into immune tolerance, immune clearance, inactivation, and reactivation. The immune clearance phase is the best time of antiviral therapy. The clinical diagnosis requires a combination of virology, liver enzyme, prothrombin activity (PTA), history, and medical imaging to make a comprehensive assessment, which results the clinical work tedious, so it is of great significance to explore new sensitive and specific biomarkers to attain efficient antiviral treatment and good prognosis.

At present, several metabolomic researches on chronic hepatitis B (CHB) have been made. However, there were no uniform biomarkers of CHB, so it might be necessary to make larger number of clinical studies. Now the relevant researches are shown as in Table 4.

Table 4
The relevant information about researches on CHB.

2.4.2. Metabonomics Studies on Hepatitis B Virus-Induced Liver Cirrhosis

Hepatitis B virus- (HBV-) induced liver cirrhosis is often secondary to CHB. When it is found, liver usually has irreversible change and the prognosis is poor, so the detection of sensitive and specific biomarkers of early fibrosis has important clinical significance.

Till now, some researchers have made several studies on HBV-induced cirrhosis trying to find the new sensitive and specific biomarkers. However, due to some limitations, those results still could not be used as biomarkers of HBV-induced cirrhosis. Table 5 shows the contents of relevant researches.

Table 5
The main contents of metabolomic studies on HBV-induced cirrhosis.

2.4.3. Metabonomics Studies on HBV-Induced Liver Failure

Liver failure is a severe liver disease which progresses rapidly and has high mortality and poor prognosis and lacks the sensitive and specific biomarkers. We diagnose it by the combination of clinical symptoms, liver function, prothrombin activity (PTA), and medical imaging. Due to the lack of sensitive and specific markers, when liver failure was found, it might have been in progress, resulting in poor prognosis.

In China, liver failure is divided into four types: acute liver failure, subacute liver failure, acute-on-chronic liver failure, and chronic liver failure. The type determines the severity and prognosis of the disease. We usually distinguish the type by a detailed history; it means that there is certain subjectivity and limitation. So it has very important significance to detect sensitive and specific biomarkers of liver failure. At present, there are some scholars who have made some research trying to find the biomarkers. The main results will be shown in Table 6.

Table 6
The main findings of studies on liver failure.

As shown in Table 6, the main metabolites were involved in lipid metabolism disorders. It has been reported that LPCs regulate cell proliferation, tumor cell invasiveness, and inflammation and play an important role in immunity adjustment. It is helpful to further understand the pathogenesis of liver failure. However, as the current researches are limited, the extensive researches are needed to verify these.

2.4.4. Metabonomics Studies on HBV Induced Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth malignancy worldwide and is the third leading cause of cancer-related deaths worldwide. The diagnosis of HCC usually combines alpha-fetoprotein (AFP) with medical imaging. However, the specificity of AFP is poor and AFP can also increase in severe hepatitis, ovarian tumors, and embryonal tumors. Liver biopsy is the gold standard for the final diagnosis of HCC; however it is an invasive diagnostic method and brings great suffering to patients, so it is difficult to be accepted by patients. Therefore it is of importance to explore the sensitive and specific diagnostic markers.

At present, several metabolomic studies have been made to find the more sensitive and specific markers. Table 7 shows the main contents of these researches.

Table 7
The main results of relevant metabolomic studies on HCC.

As shown in Table 7, the representative metabolic disorders included lipid metabolism, bile acid metabolism and amino acid metabolism. LPCs were the most significant changes among lipid metabolism. It has been reported that LPCs regulate cell proliferation, tumor cell invasiveness, and inflammation and play an important role in immunity adjustment. Some researchers have proved that bile acids play an important role in lipid and glucose metabolism, energy consumption, and even liver regeneration. The main changed amino acids in Table 7 have some functions, including providing one-carbon unit, as raw material of gluconeogenesis and antitumor immune response. These metabolites are helpful to further understand the pathogenesis of liver cancer. However, the metabolites as diagnostic biomarkers have not reached the consensus, so further studies might be needed.

2.5. Metabonomics Studies on Autoimmune Liver Diseases

Autoimmune liver diseases include autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). The clinical diagnosis depends on liver-related antibodies, liver function, liver histology, and the excluding of hepatitis virus, drug, and alcohol to make the comprehensive score. However, because some items of the score system cannot be achieved, the accuracy decreases. Therefore, it is very necessary to explore the sensitive and specific biomarkers of autoimmune liver diseases.

Till now, there have been several researches about autoimmune liver diseases. However, there are no unified results because of the different methods and limited number. Now we will show the relevant researches results in Table 8.

Table 8
The main results of studies on autoimmune liver diseases.

3. Discussion

The main metabolites mentioned in Table 8 represented several metabolic disorders, including glucose metabolism, especially the citric acid cycle, lipid metabolism, amino acid metabolism, urea cycle, bile acid metabolism, bilirubin metabolism, gluconeogenesis, inflammation, immune response, cell regeneration, and apoptosis. These metabolisms interact with each other in liver disease and promote the development of liver disease together.

Among these metabolites, we found that PC and LPC decreased in all liver diseases and some studies found that FA reduced. At present, some studies have shown that PC is involved in lipoprotein composition [56] and plays an important role in the maintenance of cell membrane function [57]. PC could decompose into choline and LPC; choline could promote the synthesis of GSH which played the role of antioxidant [57]. In liver diseases, hepatocytes suffered an injury and oxygen free radicals increased. PC participated in the repair of cell membranes and promoted the generation of choline to synthesize GSH acting as antioxidant, so PC showed the downtrend and its degradation products showed the same trend. Some studies have found that FA is the major energy resource under pressure [58]. It could provide energy for hepatocyte to facilitate its function by β-oxidation. Moreover, FA could be converted to ketones and glucose. In liver diseases, the citric acid cycle was blocked; FA broke down to produce energy, so it could explain the decreased level of FA.

In some researches above, we can see in liver diseases, except for liver cancer, that glucose, lactic acid, and citric acid increased. Glucose and citric acid may increase with the disorder of citric acid cycle. When hepatocyte was injured, it caused the mitochondrial dysfunction, resulting in the disorder of citric acid cycle. Furthermore, the increase of glucose was accompanied by the decreased glycerol and some amino acids such as glutamate, glutamine, and valine. These substances could be converted to glucose through gluconeogenesis and then enter the glucose metabolic pathways to produce energy. In liver diseases, the aerobic metabolism was blocked; glycolysis and pentose phosphate pathway became the main glucose metabolic pathways. Glycolysis could produce large amounts of lactic acid, leading to the high lactic acid level [59, 60].

Amino acids can be divided into glucogenic amino acids, ketogenic amino acids, and glucogenic and ketogenic amino acids. In liver diseases, the aerobic metabolism was injured; glycolysis became mainly glucose metabolic pathways, producing less ATP and arousing gluconeogenesis. Glucogenic amino acids such as glutamic acid and glutamine converted into glucose, leading to the decrease of amino acids. In patients with cirrhosis, the branched-chain amino acid decreased, while the aromatic amino acids increased; the ratio of branched-chain amino acid and aromatic amino acid was out of balance. In addition, some studies have shown that high levels of aromatic amino acids, especially phenylalanine, are related to the impact of the gut microorganisms [61, 62].

The most metabolites declined in HCC, but the levels of glutamine and malic acid increased; this might be correlated with urea cycle disorders. When liver cells lost their normal function and urea cycle was injured, causing elevated blood ammonia. Glutamine as the detoxification products showed the elevated levels. Malic acid could be produced by fumaric acid and generate oxaloacetate which could promote the formation of aspartic acid in transamination process and aspartic acid was used in urea cycle. When urea cycle was disordered, aspartic acid consumption reduced, indirectly leading to malic acid accumulation.

Besides the metabolic pathways above, other metabolic pathways also involved bile acid metabolism and bilirubin metabolism. Bile acids synthesized in hepatocyte cytoplasm and microsomes and excreted into intestine through the bile duct. When liver cells were damaged, the bile acids in cytoplasm were released into blood, causing the elevated serum bile acid levels. Conjugated bilirubin came into being by unconjugated bilirubin in smooth endoplasmic reticulum of liver cells. When hepatocytes or bile duct cells swell, degeneration and necrosis and the secretion and excretion of bilirubin were in disorder, leading to the release and regurgitation of bilirubin into blood and resulting in the high serum bilirubin level.

4. Conclusion and Outlook

To date, metabolomics has had considerable progression, but as a novel technology, it also faces the challenges of methodology and application. From the methodological point, the current data analysis strongly depends on the relevant technical expertise and experience; the existed analysis instruments and techniques or data processing methods all need further development. From the application point, many liver-related metabolomics researches could only recognize the different metabolites between each group, while these metabolites had not been used as sensitive and specific markers for the diagnosis of diseases. Although metabonomics has some deficiency as mentioned above and is at the early stage of development, metabonomics application in liver disease has become a hot topic in the academic field. We believe that, with the further technological innovation, the application of metabolomics in the field of liver disease will have broad prospects in the aspects of finding the new early specific markers of different liver diseases and different stages of the same disease and providing new objective evidences for the diagnosis, treatment, and prognosis.


This paper was financially supported by the National Natural Science Foundation of China (no. 81673728).

Competing Interests

There is no conflict of interests to declare.


1. Hai T. L., Liu L., Sun H., Sun W., Wang X. The successful practice of metabolomics in medical research. Progress in Modern Biomedicine. 2007;10:1582–1584.
2. Taylor J., King R. D., Altmann T., Fiehn O. Application of metabolomics to plant genotype discrimination using statistics and machine learning. Bioinformatics. 2002;18(2):S241–S248. [PubMed]
3. Oakman C., Tenori L., Biganzoli L., et al. Uncovering the metabolomic fingerprint of breast cancer. International Journal of Biochemistry and Cell Biology. 2011;43(7):1010–1020. doi: 10.1016/j.biocel.2010.05.001. [PubMed] [Cross Ref]
4. Rooney O. M., Troke J., Nicholson J. K., Griffin J. L. High-resolution diffusion and relaxation-edited magic angle spinning 1H NMR spectroscopy of intact liver tissue. Magnetic Resonance in Medicine. 2003;50(5):925–930. doi: 10.1002/mrm.10620. [PubMed] [Cross Ref]
5. Krone N., Hughes B. A., Lavery G. G., Stewart P. M., Arlt W., Shackleton C. H. L. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS) Journal of Steroid Biochemistry and Molecular Biology. 2010;121(3–5):496–504. doi: 10.1016/j.jsbmb.2010.04.010. [PMC free article] [PubMed] [Cross Ref]
6. Drexler D. M., Reily M. D., Shipkova P. A. Advances in mass spectrometry applied to pharmaceutical metabolomics. Analytical and Bioanalytical Chemistry. 2011;399(8):2645–2653. doi: 10.1007/s00216-010-4370-8. [PubMed] [Cross Ref]
7. Wei J., Xie G., Zhou Z., et al. Salivary metabolite signatures of oral cancer and leukoplakia. International Journal of Cancer. 2011;129(9):2207–2217. doi: 10.1002/ijc.25881. [PubMed] [Cross Ref]
8. Holmes E., Antti H. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst. 2002;127(12):1549–1557. doi: 10.1039/b208254n. [PubMed] [Cross Ref]
9. Keun H. C., Ebbels T. M. D., Bollard M. E., et al. Geometric trajectory analysis of metabolic responses to toxicity can define treatment specific profiles. Chemical Research in Toxicology. 2004;17(5):579–587. doi: 10.1021/tx034212w. [PubMed] [Cross Ref]
10. Wang C., Kong H., Guan Y., et al. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Analytical Chemistry. 2005;77(13):4108–4116. doi: 10.1021/ac0481001. [PubMed] [Cross Ref]
11. Sun J., Von Tungeln L. S., Hines W., Beger R. D. Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2009;877(24):2557–2565. doi: 10.1016/j.jchromb.2009.06.033. [PubMed] [Cross Ref]
12. Nicholson J. K., Lindon J. C. Systems biology: metabonomics. Nature. 2008;455(7216):1054–1056. doi: 10.1038/4551054a. [PubMed] [Cross Ref]
13. Saxena V., Gupta A., Gowda G. A. N., Saxena R., Yachha S. K., Khetrapal C. L. 1H NMR spectroscopy for the prediction of therapeutic outcome in patients with fulminant hepatic failure. NMR in Biomedicine. 2006;19(5):521–526. doi: 10.1002/nbm.1034. [PubMed] [Cross Ref]
14. Yu K., Sheng G., Sheng J., et al. A metabonomic investigation on the biochemical perturbation in liver failure patients caused by hepatitis B virus. Journal of Proteome Research. 2007;6(7):2413–2419. doi: 10.1021/pr060591d. [PubMed] [Cross Ref]
15. Xiao F. L., Jiang S. L., Yin Y. W., Huang J. The serum metabolomics research of drug induced liver injury based on ultra performance liquid chromatography-mass spectrometry. Chinese Journal Of Microecology. 2013;6:625–638.
16. Kim J. W., Ryu S. H., Kim S., et al. Pattern recognition analysis for hepatotoxicity induced by acetaminophen using plasma and urinary 1H NMR-based metabolomics in humans. Analytical Chemistry. 2013;85(23):11326–11334. doi: 10.1021/ac402390q. [PubMed] [Cross Ref]
17. Gonzalez E., van Liempd S., Conde-Vancells J., et al. Serum UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics. 2012;8(6):997–1011. doi: 10.1007/s11306-011-0329-9. [PMC free article] [PubMed] [Cross Ref]
18. Xiong Y.-H., Xu Y., Yang L., Wang Z.-T. Gas chromatography-mass spectrometry-based profiling of serum fatty acids in acetaminophen-induced liver injured rats. Journal of Applied Toxicology. 2014;34(2):149–157. doi: 10.1002/jat.2844. [PubMed] [Cross Ref]
19. Harada S., Takebayashi T., Kurihara A., et al. Metabolomic profiling reveals novel biomarkers of alcohol intake and alcohol-induced liver injury in community-dwelling men. Environmental Health and Preventive Medicine. 2016;21(1):18–26. doi: 10.1007/s12199-015-0494-y. [PMC free article] [PubMed] [Cross Ref]
20. Chang H. S., Bai H. C., Wang M. The urine metabolomics research of patients with alcoholic liver disease. Heilongjiang Medicine and Pharmacy. 2013;5:44–45.
21. Nahon P., Amathieu R., Triba M. N., et al. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clinical Cancer Research. 2012;18(24):6714–6722. doi: 10.1158/1078-0432.ccr-12-1099. [PubMed] [Cross Ref]
22. Manna S. K., Thompson M. D., Gonzalez F. J. Application of mass spectrometry-based metabolomics in identification of early noninvasive biomarkers of alcohol-induced liver disease using mouse model. Advances in Experimental Medicine and Biology. 2015;815:217–238. doi: 10.1007/978-3-319-09614-8_13. [PubMed] [Cross Ref]
23. Li S., Liu H., Jin Y., Lin S., Cai Z., Jiang Y. Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2011;879(24):2369–2375. doi: 10.1016/j.jchromb.2011.06.018. [PubMed] [Cross Ref]
24. Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. Journal of Hepatology. 2013;59(4):859–871. doi: 10.1016/j.jhep.2013.05.044. [PubMed] [Cross Ref]
25. Rodríguez-Gallego E., Guirro M., Riera-Borrull M., et al. Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. International Journal of Obesity. 2015;39(2):279–287. doi: 10.1038/ijo.2014.53. [PubMed] [Cross Ref]
26. Ferslew B. C., Xie G., Johnston C. K., et al. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences. 2015;60(11):3318–3328. doi: 10.1007/s10620-015-3776-8. [PMC free article] [PubMed] [Cross Ref]
27. Tokushige K., Hashimoto E., Kodama K., et al. Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. Journal of Gastroenterology. 2013;48(12):1392–1400. doi: 10.1007/s00535-013-0766-5. [PMC free article] [PubMed] [Cross Ref]
28. Barr J., Vázquez-Chantada M., Alonso C., et al. Liquid chromatography−mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. Journal of Proteome Research. 2010;9(9):4501–4512. doi: 10.1021/pr1002593. [PMC free article] [PubMed] [Cross Ref]
29. von Schönfels W., Patsenker E., Fahrner R., et al. Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites. Liver International. 2015;35(1):207–214. doi: 10.1111/liv.12476. [PubMed] [Cross Ref]
30. Xiao L. L., Ya N. M., Jing Y. Z., Min D. Z., Yi M. M. Metabolomics research on nonalcoholic fatty liver disease in different phenotypes. Chinese Hepatology. 2015;2:95–100.
31. Li H., Wang L., Yan X., et al. A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. Journal of Proteome Research. 2011;10(6):2797–2806. doi: 10.1021/pr200047c. [PubMed] [Cross Ref]
32. Shao X. Metabolomics Research Ased on HPLC/TripleTOF-MS/MS of Chronic Hepatitis B at Different Stages. Changchun, China: Jilin University; 2012.
33. Zhang A., Sun H., Han Y., Yan G., Wang X. Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system. PLoS ONE. 2013;8(5) doi: 10.1371/journal.pone.0064381.e64381 [PMC free article] [PubMed] [Cross Ref]
34. Hou Y., Zhu W., Chen C., Wang Y., Duan Z., Yan C. Exploration on serum metabolic biomarkers of hepatitis B virus infected patients based on gas chromatography-mass spectrometry. Chinese Journal of Chromatography. 2015;33(4):383–388. doi: 10.3724/sp.j.1123.2014.12007. [PubMed] [Cross Ref]
35. Yue D., Zhang Y., Cheng L., et al. Hepatitis B virus X protein (HBx)-induced abnormalities of nucleic acid metabolism revealed by 1H-NMR-based metabonomics. Scientific Reports. 2016;6 doi: 10.1038/srep24430.24430 [PMC free article] [PubMed] [Cross Ref]
36. Du Z., Zhang L., Liu S. Application of liquid chromatography-mass spectrometry in the study of metabolic profiling of cirrhosis in different grades. Chinese Journal of Chromatography (Se Pu) 2011;29(4):314–319. doi: 10.3724/sp.j.1123.2011.00314. [PubMed] [Cross Ref]
37. Yin P., Wan D., Zhao C., et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Molecular BioSystems. 2009;5(8):868–876. doi: 10.1039/b820224a. [PubMed] [Cross Ref]
38. Xue R., Dong L., Wu H., Liu T., Wang J., Shen X. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clinical Chemistry and Laboratory Medicine. 2009;47(3):305–310. doi: 10.1515/CCLM.2009.083. [PubMed] [Cross Ref]
39. Su W. Q. The Serum Metabolomics Study of HBV Cirrhosis at Different Stages. Chong Qing Medical University; 2012.
40. Nie C. Y., Han T., Zhang L., et al. Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS. Journal of Viral Hepatitis. 2014;21(1):53–63. doi: 10.1111/jvh.12122. [PubMed] [Cross Ref]
41. Xiao F. L. The Serum Metabolomics Preliminary Study of Acute-on-Chronic Liver Failure, Chronic Liver Failure and Pre-Liver Failure. Hangzhou, China: Zhejiang University; 2014.
42. Zhang L., Jia X., Peng X., et al. Development and validation of a liquid chromatography-mass spectrometry metabonomic platform in human plasma of liver failure caused by hepatitis B virus. Acta Biochimica et Biophysica Sinica. 2010;42(10):688–698. doi: 10.1093/abbs/gmq078. [PubMed] [Cross Ref]
43. Zhou L., Wang Q., Yin P., et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Analytical and Bioanalytical Chemistry. 2012;403(1):203–213. doi: 10.1007/s00216-012-5782-4. [PubMed] [Cross Ref]
44. Shao Y., Zhu B., Zheng R., et al. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery. Journal of Proteome Research. 2015;14(2):906–916. doi: 10.1021/pr500973d. [PubMed] [Cross Ref]
45. Liang Q., Liu H., Wang C., Li B. Phenotypic characterization analysis of human hepatocarcinoma by urine metabolomics approach. Scientific Reports. 2016;6 doi: 10.1038/srep19763.19763 [PMC free article] [PubMed] [Cross Ref]
46. Huang Q., Tan Y., Yin P., et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Research. 2013;73(16):4992–5002. doi: 10.1158/0008-5472.CAN-13-0308. [PubMed] [Cross Ref]
47. Ressom H. W., Xiao J. F., Tuli L., et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Analytica Chimica Acta. 2012;743:90–100. doi: 10.1016/j.aca.2012.07.013. [PMC free article] [PubMed] [Cross Ref]
48. Chen T., Xie G., Wang X., et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Molecular & cellular proteomics : MCP. 2011;10(7) doi: 10.1074/mcp.m110.004945. [PMC free article] [PubMed] [Cross Ref]
49. Liu S.-Y., Zhang R.-L., Kang H., Fan Z.-J., Du Z. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World Journal of Gastroenterology. 2013;19(22):3423–3432. doi: 10.3748/wjg.v19.i22.3423. [PMC free article] [PubMed] [Cross Ref]
50. Zeng J., Yin P., Tan Y., et al. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry. Journal of Proteome Research. 2014;13(7):3420–3431. doi: 10.1021/pr500390y. [PubMed] [Cross Ref]
51. Lu Q., Yi H. H., Cong H., et al. The serum metabolomic studies in patients with hepatocellular carcinoma and cirrhosis. Chinese Journal of Analytical Chemistry. 2009;2:194–198.
52. Tan Y., Yin P., Tang L., et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Molecular & Cellular Proteomics. 2012;11(2) doi: 10.1074/mcp.m111.010694.M111.010694 [PMC free article] [PubMed] [Cross Ref]
53. Lian J.-S., Liu W., Hao S.-R., et al. A serum metabolomic analysis for diagnosis and biomarker discovery of primary biliary cirrhosis and autoimmune hepatitis. Hepatobiliary and Pancreatic Diseases International. 2015;14(4):413–421. doi: 10.1016/S1499-3872(15)60393-9. [PubMed] [Cross Ref]
54. Trottier J., Białek A., Caron P., et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Digestive and Liver Disease. 2012;44(4):303–310. doi: 10.1016/j.dld.2011.10.025. [PubMed] [Cross Ref]
55. Wang J.-B., Pu S.-B., Sun Y., et al. Metabolomic profiling of autoimmune hepatitis: the diagnostic utility of nuclear magnetic resonance spectroscopy. Journal of Proteome Research. 2014;13(8):3792–3801. doi: 10.1021/pr500462f. [PubMed] [Cross Ref]
56. Ascha M., Wang Z., Ascha M. S., et al. Metabolomics studies identify novel diagnostic and prognostic indicators in patients with alcoholic hepatitis. World Journal of Hepatology. 2016;8(10):499–508. doi: 10.4254/wjh.v8.i10.499. [PMC free article] [PubMed] [Cross Ref]
57. Zhou P., Shao L., Zhao L., et al. Efficacy of fluidized bed bioartificial liver in treating fulminant hepatic failure in pigs: a metabolomics study. Scientific Reports. 2016;6 doi: 10.1038/srep26070.26070 [PMC free article] [PubMed] [Cross Ref]
58. Serebrov V. Y., Kuzmenko D. I., Burov P. G., Sapugoltseva O. B. Activity of enzymes of a sphingomyelin cycle and concentration of products of sphingomyelin degradation in the liver of rats in dynamics of the acute toxic hepatitis. Biomeditsinskaya Khimiya. 2010;56(2):283–289. doi: 10.18097/pbmc20105602283. [PubMed] [Cross Ref]
59. McPhail M. J., Shawcross D. L., Lewis M. R., et al. Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. Journal of Hepatology. 2016;64(5):1058–1067. doi: 10.1016/j.jhep.2016.01.003. [PMC free article] [PubMed] [Cross Ref]
60. Embade N., Mariño Z., Diercks T., et al. Metabolic characterization of advanced liver fibrosis in HCV patients as studied by serum 1H-NMR spectroscopy. PLoS ONE. 2016;11(5) doi: 10.1371/journal.pone.0155094.e0155094 [PMC free article] [PubMed] [Cross Ref]
61. Ferolla S., Armiliato G., Couto C., Ferrari T. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6(12):5583–5599. doi: 10.3390/nu6125583. [PMC free article] [PubMed] [Cross Ref]
62. Giannelli V., Di Gregorio V., Iebba V., et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World Journal of Gastroenterology. 2014;20(45):16795–16810. doi: 10.3748/wjg.v20.i45.16795. [PMC free article] [PubMed] [Cross Ref]

Articles from Canadian Journal of Gastroenterology & Hepatology are provided here courtesy of Hindawi Limited